武漢佰樂博代理：Research Grade Tocilizumab
貨號：DHC36902
產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75129.html
產(chǎn)品購買聯(lián)系方式：027-65279366
產(chǎn)品介紹：Tocilizumab (Anti-Human IL6R, Humanized Antibody)是一種抗人白細胞介素-6受體(IL-6R)的中和抗體，可阻止IL-6與IL-6R的結(jié)合，從而抑制經(jīng)典和反式信號。Tocilizumab可用于類風濕性關(guān)節(jié)炎的相關(guān)研究。Tocilizumab在重癥COVID-19病毒方面的研究效果顯著。
通用名：Tocilizumab
純度：>95% by SDS-PAGE.
濃度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
內(nèi)毒素：Please contact with the lab for this information.
別名：Atlizumab, MRA, R-1569, RHPM-1, RO-4877533
靶點;物種：Human CD126/IL6R/IL-6RA
種類：Humanized
受體鑒定：IgG1
CAS: 375823-41-9
存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
參考文獻：
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. PMID: 30528964
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. PMID: 29385370
ESCMID COVID-19 living guidelines: drug treatment and clinical management. PMID: 34823008
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. PMID: 31320380
Current concepts in the diagnosis and management of cytokine release syndrome. PMID: 24876563
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. PMID: 33827116
Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. PMID: 34718159
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. PMID: 34296427
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. PMID: 34590303
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. PMID: 23527958
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. PMID: 32929488
Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. PMID: 35863630
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. PMID: 34712233
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. PMID: 33161150
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge. PMID: 35453540
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PMID: 33378357
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. PMID: 34619768
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. PMID: 35154124
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. PMID: 36096534
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma. PMID: 35432352
Toxicities of CD19 CAR-T cell immunotherapy. PMID: 30784102
Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. PMID: 36636447
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. PMID: 29880584
Atherosclerosis: perspectives of anti-inflammatory therapy. PMID: 30701884
Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. PMID: 34151714
Managing juvenile idiopathic arthritis-associated uveitis. PMID: 26599495
Tocilizumab for steroid refractory acute graft-versus-host disease. PMID: 26140610
Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. PMID: 35015687
Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. PMID: 32776808
Consensus statement and recommendations on the treatment of COVID-19: 2021 update. PMID: 34524227
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). PMID: 31856966
Japanese rapid/living recommendations on drug management for COVID-19. PMID: 34178358
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. PMID: 33546739
Acute Graft-versus-Host Disease: Emerging Insights and Updates into Detection, Prevention, and Treatment. PMID: 32530080
Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. PMID: 30244217
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. PMID: 33462203
Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges. PMID: 35492871
Disentangling the effects of tocilizumab on neutrophil survival and function. PMID: 26721805
Role of interleukin-6 in stress, sleep, and fatigue. PMID: 22823398
Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. PMID: 31823144
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. PMID: 27913530
The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. PMID: 35848998
Targeting gp130 to prevent inflammation and promote insulin action. PMID: 24003934
Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. PMID: 35799791
